Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Further strengthens BaseLaunch's global pharma industry partnerships
Subscribe To Our Newsletter & Stay Updated